Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms and aims to provide high-quality, safe, and effective drugs and services globally [2]. - The main business segments include heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7]. - As of June 30, 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Cumulative cash dividends since the A-share listing amount to 4.21 billion yuan, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 27, Haiprime's stock rose by 0.84%, with a trading volume of 46.599 million yuan and a market capitalization of 17.622 billion yuan [1]. - The stock has seen a net inflow of 2.6047 million yuan from major investors today, indicating a slight increase in interest [4]. Technical Analysis - The average trading cost of the stock is 11.56 yuan, with the current price fluctuating between resistance at 12.80 yuan and support at 11.53 yuan, suggesting potential for range trading [6].

Core Viewpoint - The company Haiprui is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms. Its main business includes the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company’s revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. Financial Performance - For the first half of 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, the company had a total market capitalization of 17.564 billion yuan [1]. Market Position - The company has a significant overseas revenue share of 93.04%, which is positively impacted by the depreciation of the RMB [3]. - The stock has shown a recent trading volume of 46.8377 million yuan with a turnover rate of 0.31% [1]. Shareholder Information - As of June 30, 2025, Haiprui had 26,300 shareholders, a decrease of 7.29% from the previous period [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.3765 million shares [9]. Dividend History - Since its A-share listing, Haiprui has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].

Core Viewpoint - The market showed mixed performance with the Shanghai Composite Index slightly declining while the North Exchange 50 Index gained strength, indicating a potential recovery in investor sentiment and market dynamics [1] Market Performance - The Shanghai Composite Index closed down 0.07% at 3913.76 points, the Shenzhen Component Index fell 0.62% to 12996.61 points, and the ChiNext Index decreased by 0.79% to 3059.32 points [1] - The North Exchange 50 Index increased by 0.87%, with a total trading volume across the Shanghai, Shenzhen, and North exchanges reaching 16,905 billion [1] Sector Analysis - Sectors such as coal, non-ferrous metals, brokerage, and semiconductors experienced declines, while oil and real estate sectors showed strong gains [1] - Banking, pharmaceuticals, and retail sectors also saw upward movement, with emerging concepts like lab-grown meat, marine economy, and biovaccines becoming active [1] Investment Strategy - According to China Merchants Securities, there is still an inflow of incremental capital into the market, with strong investor willingness to accumulate positions at lower levels, suggesting a potential market rebound [1] - Short-term focus should be on previously popular sectors such as domestic computing power, semiconductor autonomy, controllable nuclear fusion, military industry, and commercial aerospace, while long-term strategies should consider the potential economic resonance between China and the U.S. in 2026 and the trend of PPI recovery, emphasizing low-position cyclical sectors [1]

Core Viewpoint - The market is experiencing a downward trend with the Shanghai Composite Index falling by 0.44% and various sectors such as coal and non-ferrous metals declining, while the artificial meat concept remains active [1] Market Performance - As of the midday close, the Shanghai Composite Index is at 3899.05 points, down 0.44%, the Shenzhen Component is down 0.81%, and the ChiNext Index is down 0.89%. In contrast, the North China 50 Index has risen by 1.19% [1] - The total trading volume across the Shanghai, Shenzhen, and North exchanges reached 1.1142 trillion yuan [1] Sector Analysis - Sectors such as coal, non-ferrous metals, semiconductors, and brokerage firms are experiencing declines, while engineering machinery, real estate, oil, and pharmaceuticals are seeing gains. The artificial meat, industrial mother machines, and biological vaccine concepts are particularly active [1] Economic Outlook - Dongguan Securities indicates that the index has reached a high point, leading to increased capital divergence and potential short-term fluctuations due to profit-taking. However, as tariff disturbances are gradually resolved, the economy is expected to continue recovering in the fourth quarter supported by policy measures [1] - The expectation of interest rate cuts by the Federal Reserve may attract foreign capital inflows, while the decline in domestic risk-free interest rates enhances the investment value of A-shares, potentially driving more domestic capital into the stock market [1] Investment Strategy - The market may face short-term fluctuations, but the medium-term upward trend is expected to continue. It is advised to maintain flexible positions, avoid blind chasing of highs, and actively adjust holdings based on economic conditions and valuation [1]

Core Viewpoint - Haiprime's stock increased by 2.14% with a trading volume of 39.77 million yuan and a total market capitalization of 17.52 billion yuan, indicating positive market sentiment towards the company [1] Group 1: Company Overview - Haiprime, established in 1998 in Shenzhen, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2] - The company's main business segments include 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7] - As of June 30, 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7] Group 2: Financial Performance - The company benefits from a high overseas revenue ratio of 93.04%, positively impacted by the depreciation of the yuan [3] - Haiprime has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8] Group 3: Market Position and Trends - The stock's average trading cost is 11.56 yuan, with recent trading activity showing a decrease in holdings but at a slowing rate; the current stock price is between resistance at 12.33 yuan and support at 11.16 yuan, suggesting potential for range trading [6] - The main capital inflow today was 3.48 million yuan, accounting for 0.09% of the total, with the stock showing no clear trend in major capital movements [4][5]

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with both A and H share financing platforms, primarily engaged in the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business revenue composition includes: 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. Financial Performance - For the first half of 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, the company had a total market capitalization of 17.153 billion yuan, with a trading volume of 35.1323 million yuan on October 20, 2023 [1][7]. Market Position - Haiprime's overseas revenue accounted for 93.04% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is positioned within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and chemical preparations [7]. Shareholder Information - As of June 30, 2025, Haiprime had 26,300 shareholders, a decrease of 7.29% from the previous period, with an average of 0 shares per shareholder [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.3765 million shares to 11.3176 million shares [9]. Dividend Distribution - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, low molecular weight heparin products, and biopharmaceutical CDMO services [7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Market Activity - On October 16, Haiprui's stock price decreased by 0.17%, with a trading volume of 45.1938 million yuan and a turnover rate of 0.31%, resulting in a total market capitalization of 17.299 billion yuan [1]. - The stock's average trading cost is 11.57 yuan, with current price fluctuations between resistance at 12.33 yuan and support at 11.16 yuan [6]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with no circulating shares per person [7]. - The eighth largest shareholder is Hong Kong Central Clearing Limited, holding 11.3176 million shares, an increase of 6.3765 million shares from the previous period [9].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, downstream low molecular weight heparin products, and CDMO services for biopharmaceuticals [7]. - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 11.57 yuan, with the current stock price fluctuating between resistance at 12.33 yuan and support at 11.16 yuan [6]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300 [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 14, Haiprui's stock fell by 1.53%, with a trading volume of 59.5826 million yuan and a turnover rate of 0.41%, resulting in a total market capitalization of 16.962 billion yuan [1].

Core Viewpoint - The company Haiprui experienced a decline of 1.68% in stock price, with a trading volume of 47.80 million yuan and a total market capitalization of 17.23 billion yuan [1] Company Overview - Haiprui, established in 1998 in Shenzhen, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7] - The main business revenue composition includes formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7] Financial Performance - For the first half of 2025, Haiprui reported a revenue of 2.82 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7] - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8] Market Position and Trends - As of the 2024 annual report, overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the yuan [3] - The company operates in the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and chemical preparations, with concepts including raw materials, heparin, biopharmaceuticals, innovative drugs, and vaccines [7] Institutional Holdings - As of June 30, 2025, the eighth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 11.32 million shares, an increase of 6.38 million shares from the previous period [9]

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 and listed in 2010, Hepalink operates primarily in the heparin industry, with its main business segments including formulations (63.06%), CDMO (18.59%), and heparin raw materials (16.05%) [7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization of Hepalink is 17.666 billion yuan, with a trading volume of 37.9727 million yuan on September 25, 2023 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with the average circulating shares per person remaining at zero [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On September 25, 2023, the stock price of Hepalink fell by 1.15%, with a turnover rate of 0.25% [1]. - The stock is currently near a resistance level of 12.33 yuan, with an average trading cost of 11.57 yuan [6].